DraftNeighborhood Health Plan of Rhode IslandPolicy UM ONC_1516

Unloxcyt (cosibelimab-ipdl) drug policy — coverage criteria

Defines coverage, inclusion and exclusion criteria, coding, and utilization management requirements for Unloxcyt (cosibelimab-ipdl) for members of Neighborhood Health Plan of Rhode Island via Evolent’s UM program.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyUnloxcyt (cosibelimab-ipdl) drug policy — coverage criteria

Policy CodePolicy UM ONC_1516

Change TypeNew drug-specific policymaterial additions (coverage, dosing cap, exclusions)

Effective DateJanuary 31,2025

Next Review Date

Key ActionSubmit prior authorization with supporting FDA labeling or CMS‑recognized compendia/NCCN/ASCO evidence.

SourceLink

POLICY UPDATE CHANGES

Policy establishes Unloxcyt (cosibelimab-ipdl) coverage for adult metastatic or locally advanced cutaneous squamous cell carcinoma when patients are not candidates for curative surgery or radiation.

Single dose limit specified: dosing exceeds single dose limit of 1200 mg is excluded.

Prior anti-PD-1/PD-L1 or other immune checkpoint inhibitor therapy is listed as an exclusion.

1200 mgsingle dose limit

2025-01-08committee approval

2025-01-31effective date

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Unloxcyt (cosibelimab-ipdl)

Initial therapy (Indication + Evidence)

Covered when ALL of the following are met

Indication: Member is an adult with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced cutaneous squamous cell carcinoma (laCSCC) who is not a candidate for curative surgery or curative radiation.

Supported by FDA labeling or accepted compendia/guidelines

Evidence: Use is supported by FDA product labeling, CMS‑recognized compendia, NCCN or ASCO guidelines, or peer‑reviewed literature meeting CMS standards.

Per policy purpose: required supporting evidence

Continuation therapy

Covered when ALL of the following are met

No disease progression: Member has not experienced disease progression while on Unloxcyt.

Continuation exemption requires no progression

Authorization continuity: Requested medication was used within the last year without a lapse of more than 30 days of having an active authorization.

Continuation exemption condition

Coverage is not approved when any of the following apply: disease progression while receiving Unloxcyt (cosibelimab-ipdl); concurrent use with other anticancer therapies; or prior treatment with anti‑PD‑1/PD‑L1 blocking antibodies or other immune checkpoint inhibitor therapy. Additionally, dosing that exceeds the single dose limit of 1200 mg will be excluded.

Use of Unloxcyt (cosibelimab-ipdl) for off‑label indications that are not supported by adequate evidence is considered investigational and not approvable. Adequate evidence is defined by the policy as support from CMS‑recognized compendia or acceptable peer‑reviewed literature; factors include whether the patient and cancer characteristics and the administered regimen are represented in the published evidence, whether outcomes reported are clinically meaningful (for example, ASCO‑type thresholds such as hazard ratio < 0.80 or survival benefits of at least 3 months for OS/PFS), and whether study design and size provide reliable support. Case reports and meeting abstracts without full peer‑reviewed publication are generally insufficient.

Billing & Coding

Billing HCPCSHCPCS

J9999

cosibelimab-ipdl

Single dose limit — operational dosing cap

Single dose limit1200 mg per single dose — dosing that exceeds a single dose limit of 1200 mg is excluded.

ApplicabilityLimit applies to Unloxcyt (cosibelimab-ipdl) dosing for authorization decisions.

EnforcementRequests with dosing >1200 mg may be denied per exclusion criteria.

Provider Actions & Authorization Requirements

Prior Authorization

Prior Authorization Required

Prior Authorization is required for Unloxcyt (cosibelimab‑ipdl). Requests must be submitted to Evolent for review prior to drug administration. This applies to adult members with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced cutaneous squamous cell carcinoma (laCSCC) who are not candidates for curative surgery or curative radiation.

Applies to initial requests and dose increases exceeding single‑dose limit of 1200 mg.
Continuation requests for previously authorized therapy may be eligible for exemption when continuation criteria are met (see documentation callout).

Prior Authorization

Continuation Exemption

Continuation requests for previously authorized Unloxcyt are exempt from a new prior authorization when ALL of the following are met: the member has not experienced disease progression on Unloxcyt; the medication was used within the last year without a lapse of more than 30 days since the end of the prior authorization; and there is no change in indication or dosing outside previously authorized parameters.

Exemption does not apply if disease progression has occurred, if requesting concurrent anticancer therapies, or if requested dosing exceeds single dose limit of 1200 mg.

Background

Unloxcyt (cosibelimab‑ipdl) is an immune checkpoint inhibitor in the class of anti–PD‑L1 monoclonal antibodies developed for use in cutaneous squamous cell carcinoma. The policy applies to adult members with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC/laCSCC) who are not candidates for curative surgery or curative radiation, and specifies that authorization must be supported by FDA labeling or recognized compendia/guidelines. Medication management details and FDA labeling should be referenced for dosing and administration guidance.

Key Definitions

mCSCC / laCSCC — eligibility definition

Defined disease statesMetastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced cutaneous squamous cell carcinoma (laCSCC).

Patient populationAdult members only.

Surgical/radiation candidacyMember is not a candidate for curative surgery or curative radiation.

Initial Authorization Criteria

Initial therapy criteria

Initial authorization requirements

Age: Patient is an adult.

Per indication

Disease state: Metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced cutaneous squamous cell carcinoma (laCSCC) not amenable to curative surgery or curative radiation.

Per indication

Evidence support: Request is supported by FDA product labeling, CMS‑recognized compendia, NCCN or ASCO guidelines, or peer‑reviewed literature that meets CMS standards.

Per policy purpose

Continuation Therapy Criteria

Continuation therapy rules

Continuation requests exemption and rules

No progression: Member has not experienced disease progression on the requested medication.

Continuation exemption condition

Recent prior use: Requested medication was used within the last year without a lapse of more than 30 days of having an active authorization.

Continuation exemption condition

Step Therapy Requirements

Step	Requirement	Failure criterion
1	No prior checkpoint inhibitor therapy (member must have no prior treatment with anti‑PD‑1/PD‑L1 blocking antibodies or other immune checkpoint inhibitor therapy).	Prior treatment with an anti‑PD‑1/PD‑L1 or other immune checkpoint inhibitor — request is not approvable.

Quantity Limits

Unloxcyt (cosibelimab-ipdl) — quantity limit (1200)

DrugUnloxcyt (cosibelimab-ipdl) — HCPCS J9999.

Quantity limit1200 mg per dose (operational limit).

UnitMilligrams (mg) per single dose.

Site of Care

Note

Infusion center/site-of-care guidance

Site of care is not specified in this policy; providers should follow the member’s plan coverage and FDA labeling regarding infusion center use and other medication management details.

Refer to the member’s plan for coverage determinations about infusion centers.
Refer to the FDA label for medication administration and management instructions.

Revision History & Policy Changes

2025-01-08committee_approval

Evolent Specialty Services Clinical Guideline Review Committee approved the new Unloxcyt (cosibelimab‑ipdl) drug policy (UM ONC_1516).

2025-01-31policy_effectiveLatest

Policy became effective establishing coverage criteria for Unloxcyt (cosibelimab‑ipdl) for adult members with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.

2025-01-08material_change_added

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyUnloxcyt (cosibelimab-ipdl) drug policy — coverage criteria

Policy CodePolicy UM ONC_1516

Change TypeNew drug-specific policymaterial additions (coverage, dosing cap, exclusions)

Effective DateJanuary 31,2025

Next Review Date

Key ActionSubmit prior authorization with supporting FDA labeling or CMS‑recognized compendia/NCCN/ASCO evidence.

SourceLink

On This Page

Documentation Required

Required Supporting Documentation

Authorization requests must be supported by documentation demonstrating the requested use is consistent with accepted sources. Acceptable supporting documentation includes FDA‑approved product labeling; CMS‑recognized compendia; National Comprehensive Cancer Network (NCCN) or American Society of Clinical Oncology (ASCO) clinical guidelines; or peer‑reviewed medical literature that meets CMS evidence standards (see policy Purpose). Documentation should clearly demonstrate the member meets clinical inclusion criteria and none of the exclusion criteria apply.

Include relevant excerpts or citations from FDA labeling, NCCN/ASCO guidelines, or CMS compendia when applicable.
Provide clinical notes, pathology reports, imaging, prior authorization history, and treatment dates to support continuation requests and to document absence of disease progression.
If relying on peer‑reviewed literature, include full reference and rationale that the evidence meets CMS Medicare Benefit Policy Manual Chapter 15 standards (e.g., study population applicability, clinically meaningful outcomes).

Denial Risk

Triggers for Denial / Risk of Non‑Approval

Authorization may be denied when any exclusion criteria are present or documentation is insufficient. Common triggers for denial include documented disease progression on Unloxcyt, concurrent use with other anticancer therapies, prior treatment with anti‑PD‑1/PD‑L1 or other checkpoint inhibitors, dosing requests exceeding the single dose limit of 1200 mg, or use for investigational/off‑label indications not supported by acceptable evidence.

Requests lacking adequate supporting evidence from FDA labeling, CMS compendia, NCCN/ASCO, or acceptable peer‑reviewed literature will be denied.
Requests for unapproved or investigational indications without sufficient published evidence (e.g., only case reports or abstracts) are not approvable.

New drug‑specific policy created and approved; policy defines coverage, inclusion/exclusion criteria, and utilization management for Unloxcyt (cosibelimab‑ipdl).

2025-01-08material_change_added

Operational single‑dose limit of 1200 mg was specified for authorization decisions (dosing exceeding single dose limit excluded).

2025-01-08material_change_added

Prior treatment with anti‑PD‑1/PD‑L1 or other immune checkpoint inhibitors was added as an exclusion preventing approval under this policy.